Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9

• Published in: Acta pharmacologica Sinica Vol. 43; no. 11; pp. 2946 - 2955
• Main Authors: Liang, Lu, Xu, Wen-yan, Shen, Ao, Cen, Hui-yu, Chen, Zhi-jun, Tan, Lin, Zhang, Ling-min, Zhang, Yu, Fu, Ji-jun, Qin, Ai-ping, Lei, Xue-ping, Li, Song-pei, Qin, Yu-yan, Huang, Jiong-hua, Yu, Xi-yong
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.11.2022; Nature Publishing Group
• Subjects: Adenocarcinoma; Adenocarcinoma of Lung - genetics; Animals; Biomedical and Life Sciences; Biomedicine; Carcinoma, Non-Small-Cell Lung - genetics; Cell Line, Tumor; Cell migration; Cell Movement; Cell Proliferation - genetics; Cytoskeleton; DNA methylation; Gene Expression Regulation, Neoplastic; Humans; Immunology; Internal Medicine; Kinases; Lung cancer; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Lymph nodes; MAP Kinase Kinase Kinases - genetics; MAP Kinase Kinase Kinases - metabolism; Medical Microbiology; Mesenchyme; Metastases; Metastasis; Methylation; Mice; MicroRNAs; MicroRNAs - genetics; MicroRNAs - metabolism; miRNA; Non-small cell lung carcinoma; Pharmacology/Toxicology; Small cell lung carcinoma; Therapeutic targets; Tumor cell lines; Tumor suppressor genes; Tumors; Vaccine; Xenografts; miR-148a-3p; MAP3K9; metastasis; EMT; methylation; lung adenocarcinoma

Lung adenocarcinoma (LUAD) characterized by high metastasis and mortality is the leading subtype of non-small cell lung cancer. Evidence shows that some microRNAs (miRNAs) may act as oncogenes or tumor suppressor genes, leading to malignant tumor occurrence and progression. To better understand the...